Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction Research Letter
| Authors: | Fu, W.; Chen, Y.; Wang, K.; Hettinghouse, A.; Hu, W.; Wang, J. Q.; Lei, Z. N.; Chen, Z. S.; Stapleford, K. A.; Liu, C. J. |
| Title: | Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction |
| Keywords: | protein expression; unclassified drug; diarrhea; flow cytometry; letter; t lymphocyte; gene overexpression; inflammation; calcitriol; cytotoxicity; food and drug administration; enzyme linked immunosorbent assay; cost effectiveness analysis; disease severity; paracetamol; retinopathy; hydrogen bond; vitamin d deficiency; virus replication; enzyme-linked immunosorbent assay; molecular docking; screening test; glycoprotein; socioeconomics; glutathione; cysteine; antiviral activity; cyclin dependent kinase 1; clinical trial (topic); pharmaceutical preparations; photosensitizing agent; drug; verteporfin; virus neutralization; acetylcysteine; dipeptidyl carboxypeptidase; dithiothreitol; humans; human; benzoporphyrin derivative; drug repositioning; acetorphan; ic50; virus spike protein; mercaptoethanol; peptidyl-dipeptidase a; ec50; hek293t cell line; severe acute respiratory syndrome coronavirus 2; covid-19; angiotensin converting enzyme 2; sars-cov-2; viral protein; enkephalinase inhibitor; receptor binding domain; tiopronin; cc50 (cytotoxic concentration) |
| Journal Title: | Protein & Cell |
| Volume: | 12 |
| Issue: | 7 |
| ISSN: | 1674-800X |
| Publisher: | Higher Education Press |
| Date Published: | 2021-07-01 |
| Start Page: | 586 |
| End Page: | 591 |
| Language: | English |
| DOI: | 10.1007/s13238-020-00803-w |
| PUBMED: | 33210243 |
| PROVIDER: | scopus |
| PMCID: | PMC7673315 |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 1 September 2021 -- Source: Scopus |
